Azopharma Product Development Group, Inc. has acquired Analytical Development Corporation (ADC), a bioanalytical lab located in Colorado Springs, CO. ADC, founded in 1971 as a CRO providing bioanalytical services to the pharmaceutical and biotechnology industries, will operate under the name ADMEquant Bioanalytical Services. The acquisition enhances Azopharma’s product development services and provides a dedicated lab to support its preclinical and clinical projects.
   
The ADMEquant facility has 17,000 sq. ft. of lab and office space, including 7,500 cubic feet of temperature-monitored freezer/refrigerator storage. The staff includes professionals averaging more than 20 years of experience in analytical chemistry with expertise in ADME and metabolism studies.  
   
ADMEquant’s analytical capabilities include: methods development, methods validation, preclinical support, clinical support, proprietary methods, all matrices and species, LC/MS/MS, HPLC, GC and LSC, GLP, GCP and cGMP compliant.
   
According to Phil Meeks, Azopharma’s chief executive officer, “The knowledge and experience at ADMEquant adds a lot to the Azopharma Product Development Group. Their experience supporting preclinical and clinical studies lifts the level of service and capabilities we can provide to our clients.”  Mr. Meeks added, “With last year’s acquisition of AniClin Preclinical Services and this January’s acquisition of AvivoClin Clinical Services, we wanted to add a world class bioanalytical laboratory. Acquiring ADMEquant gives us access to a large library of methods and additional instrumentation capacity to support large scale early and late stage programs.”